ClinicalTrials.gg

Program

cannabis sativa flowering TOP

Also written as “Cannabis oil”, “MGCND00EP1” and “Medical Grade Cannabis oil”.

Its studies are mostly in Drug Resistant Epilepsy · Attention Deficit Disorder with Hyperactivity · Autistic Disorder · Hidradenitis Suppurativa, led by 5 companies.

Furthest: phase 2, since Apr 24, 20196 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TO Pharmaceuticals20 open or runningphase 2since Apr 24, 2019Apr 24, 2019none ahead
Brlev Agricultural Crops10 open or runningphase 2since Dec 30, 2021Dec 30, 2021none ahead
GreenCare Pharma11 open or runningphase 1since Jan 17, 2025Jan 17, 2025none ahead
MGC Pharmaceuticals d.o.o10 open or runningphase 2since May 17, 2020May 17, 2020none ahead
New Age Ventures10 open or runningphase 1since Jul 29, 2020Jul 29, 2020none ahead

Also a collaborator on its studies: Bio-Sciences Pharma and KGK Science.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2019First studies: 2 phase 2 studiesNew to TO PharmaceuticalsTO Pharmaceuticals · NCT05413187, NCT03929835
  2. May 17, 2020MGC Pharmaceuticals d.o.o’s first study: phase 2 study in Drug Resistant EpilepsyNew to MGC Pharmaceuticals d.o.oMGC Pharmaceuticals d.o.o · NCT04406948 · Israel, Slovenia
  3. Jul 29, 2020New Age Ventures’ first study: phase 1 study in Marijuana AbuseNew to New Age VenturesNew Age Ventures · NCT04601207 · 32 enrolled · Canada
  4. Dec 30, 2021Brlev Agricultural Crops’ first study: phase 2 study in Attention Deficit Disorder with HyperactivityNew to Brlev Agricultural CropsBrlev Agricultural Crops · NCT05219370 · 8 enrolled · Israel
  5. Jan 17, 2025GreenCare Pharma’s first study: phase 1 study in HealthyNew to GreenCare PharmaGreenCare Pharma · NCT06807762 · 72 planned · Brazil

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06807762Healthy · Brazil1RecruitingGreenCare PharmaJun 202572
NCT05219370Attention Deficit Disorder with Hyperactivity · Israel2TerminatedBrlev Agricultural CropsDec 31, 20228
NCT04601207Marijuana Abuse · Canada1CompletedNew Age VenturesNov 30, 202032
NCT04406948Drug Resistant Epilepsy · Israel, Slovenia2WithdrawnMGC Pharmaceuticals d.o.oMay 30, 20240
NCT05413187Autistic Disorder · Israel2WithdrawnTO PharmaceuticalsSep 1, 20220
NCT03929835Hidradenitis Suppurativa · Israel2WithdrawnTO PharmaceuticalsSep 1, 20220

How it is read

Names in the registry

  • “Cannabis oil”, 3 entries
  • “MGCND00EP1”, 1 entry
  • “Medical Grade Cannabis oil”, 1 entry
  • “Cannabis Preparation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
cannabis sativa flowering TOP (TO Pharmaceuticals): development program | ClinicalTrials.gg